Eduardo Obraczka

Eduardo Obraczka - Ipsen US LeadershipVice President and Franchise Head, Rare Diseases North America

Eduardo brings more than 20 years of experience building and leading high-performing teams.

His broad background spans across multiple roles at global, regional, and local levels and has provided him the opportunity to lead organizations of various sizes and complexities. Most recently, Eduardo led the Business Operations and Strategy team and was Chief of Staff to the President of North America at Ipsen.

Prior to joining Ipsen, Eduardo served as General Manager for a medical device start-up in Brazil as well as the Managing Director for Merck KGaA’s operations in Colombia, where he led the transformation of the primary care, specialty care and rare diseases businesses into the fastest growing pharmaceutical company in the country. In addition, Eduardo has held international roles with Merck KGaA, Merck Sharp & Dohme, and Sanofi Pasteur, gaining marketing, commercial leadership, brand development, product launch, strategic planning, and organizational design experience. Eduardo began his career in investment banking and private equity.

Eduardo received a Bachelor of Science in Industrial Engineering from Federal University of Rio de Janeiro in Brazil and an MBA from Yale University.

Our mission?

To improve patients’ lives

Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care. We help patients through our expertise in oncology, neuroscience, and rare disease.

Find out more about us or see other members of our leadership team.


Products and partnerships

Our products

Our mission is to improve patients’ lives.

See our products


Access our development and commercialization teams. We take bold steps to translate your science and innovations into solutions that make a difference for patients in need.

See more on partnering

Products and partnerships

What’s happening now?

See the latest
©2022 Ipsen Biopharmaceuticals, Inc. MP-US-000472 June 2022